Concepts (299)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Alzheimer Disease | 23 | 2017 | 291 | 2.470 |
Why?
|
Cognition | 20 | 2019 | 512 | 2.090 |
Why?
|
Growth Hormone-Releasing Hormone | 4 | 2018 | 7 | 1.200 |
Why?
|
Neuropsychological Tests | 22 | 2019 | 370 | 1.080 |
Why?
|
Postmenopause | 7 | 2019 | 398 | 1.060 |
Why?
|
Insulin | 12 | 2015 | 364 | 1.060 |
Why?
|
Exercise | 8 | 2019 | 567 | 0.980 |
Why?
|
Hormones | 2 | 2013 | 20 | 0.910 |
Why?
|
Cognition Disorders | 8 | 2013 | 388 | 0.910 |
Why?
|
Glucose | 4 | 2013 | 163 | 0.870 |
Why?
|
Insulin Resistance | 7 | 2019 | 494 | 0.830 |
Why?
|
Aged | 48 | 2019 | 9256 | 0.810 |
Why?
|
Exercise Therapy | 3 | 2019 | 195 | 0.780 |
Why?
|
Cacao | 1 | 2019 | 4 | 0.720 |
Why?
|
Aged, 80 and over | 26 | 2019 | 3562 | 0.710 |
Why?
|
Double-Blind Method | 16 | 2019 | 480 | 0.700 |
Why?
|
Estradiol | 3 | 2011 | 120 | 0.700 |
Why?
|
Peptide Fragments | 8 | 2018 | 480 | 0.700 |
Why?
|
Female | 53 | 2019 | 17679 | 0.700 |
Why?
|
Hypovolemia | 1 | 2018 | 3 | 0.690 |
Why?
|
Vitamins | 1 | 2019 | 56 | 0.690 |
Why?
|
Phlebotomy | 1 | 2018 | 17 | 0.680 |
Why?
|
Plant Extracts | 1 | 2019 | 59 | 0.680 |
Why?
|
Blood Loss, Surgical | 1 | 2018 | 41 | 0.680 |
Why?
|
Erythrocyte Transfusion | 1 | 2018 | 31 | 0.670 |
Why?
|
Hepatectomy | 1 | 2018 | 65 | 0.660 |
Why?
|
Dietary Supplements | 1 | 2019 | 171 | 0.640 |
Why?
|
Brain | 7 | 2017 | 809 | 0.630 |
Why?
|
Sleep Initiation and Maintenance Disorders | 5 | 2019 | 48 | 0.630 |
Why?
|
Diabetes Mellitus, Type 2 | 7 | 2019 | 1556 | 0.610 |
Why?
|
Male | 46 | 2019 | 16967 | 0.610 |
Why?
|
Humans | 61 | 2019 | 28304 | 0.610 |
Why?
|
Middle Aged | 31 | 2019 | 10678 | 0.560 |
Why?
|
Memory | 8 | 2018 | 175 | 0.560 |
Why?
|
Apolipoprotein E4 | 9 | 2015 | 58 | 0.550 |
Why?
|
Hypoglycemic Agents | 6 | 2015 | 177 | 0.520 |
Why?
|
Follow-Up Studies | 11 | 2018 | 2027 | 0.500 |
Why?
|
Aging | 5 | 2013 | 857 | 0.490 |
Why?
|
Sleep | 5 | 2019 | 75 | 0.450 |
Why?
|
Osteoarthritis | 4 | 2014 | 72 | 0.440 |
Why?
|
Glucose Intolerance | 2 | 2010 | 44 | 0.440 |
Why?
|
Estrogens | 2 | 2011 | 170 | 0.420 |
Why?
|
Diet, Fat-Restricted | 1 | 2012 | 30 | 0.420 |
Why?
|
Life Style | 5 | 2018 | 372 | 0.410 |
Why?
|
Hydrocortisone | 1 | 2011 | 53 | 0.410 |
Why?
|
Executive Function | 5 | 2019 | 51 | 0.390 |
Why?
|
Cerebral Cortex | 1 | 2010 | 82 | 0.370 |
Why?
|
Prediabetic State | 1 | 2010 | 55 | 0.370 |
Why?
|
Motor Activity | 1 | 2012 | 251 | 0.360 |
Why?
|
Physical Fitness | 2 | 2010 | 114 | 0.360 |
Why?
|
Lipid Metabolism | 3 | 2015 | 102 | 0.340 |
Why?
|
Dementia | 5 | 2019 | 231 | 0.330 |
Why?
|
Overweight | 4 | 2018 | 254 | 0.310 |
Why?
|
Time Factors | 7 | 2019 | 1874 | 0.310 |
Why?
|
Estrogen Replacement Therapy | 2 | 2011 | 183 | 0.300 |
Why?
|
Treatment Outcome | 15 | 2019 | 2886 | 0.300 |
Why?
|
Insulin-Like Growth Factor I | 3 | 2012 | 74 | 0.300 |
Why?
|
Hormone Replacement Therapy | 2 | 2017 | 88 | 0.280 |
Why?
|
Affect | 3 | 2012 | 53 | 0.240 |
Why?
|
Caloric Restriction | 2 | 2019 | 92 | 0.200 |
Why?
|
Longitudinal Studies | 7 | 2019 | 694 | 0.200 |
Why?
|
Analysis of Variance | 5 | 2015 | 390 | 0.200 |
Why?
|
Absorptiometry, Photon | 2 | 2012 | 130 | 0.200 |
Why?
|
Sulfonamides | 3 | 2011 | 67 | 0.200 |
Why?
|
Obesity | 5 | 2019 | 1079 | 0.190 |
Why?
|
Diet | 2 | 2013 | 346 | 0.190 |
Why?
|
Anti-Inflammatory Agents, Non-Steroidal | 2 | 2011 | 68 | 0.190 |
Why?
|
Risk Factors | 4 | 2018 | 3520 | 0.180 |
Why?
|
Problem Solving | 2 | 2018 | 27 | 0.180 |
Why?
|
Genotype | 5 | 2013 | 813 | 0.180 |
Why?
|
Central Venous Pressure | 1 | 2018 | 4 | 0.170 |
Why?
|
Gyrus Cinguli | 2 | 2016 | 15 | 0.170 |
Why?
|
Amnesia | 2 | 2011 | 10 | 0.170 |
Why?
|
Colorectal Surgery | 1 | 2018 | 2 | 0.170 |
Why?
|
Estrogens, Conjugated (USP) | 2 | 2017 | 125 | 0.170 |
Why?
|
Killer Cells, Natural | 1 | 2018 | 24 | 0.170 |
Why?
|
Interferon-gamma | 1 | 2018 | 52 | 0.170 |
Why?
|
Cohort Studies | 7 | 2018 | 1673 | 0.170 |
Why?
|
Heart Rate | 2 | 2010 | 325 | 0.160 |
Why?
|
Dietary Fats | 2 | 2015 | 107 | 0.150 |
Why?
|
Randomized Controlled Trials as Topic | 1 | 2019 | 441 | 0.150 |
Why?
|
Liver Neoplasms | 1 | 2018 | 161 | 0.150 |
Why?
|
Nootropic Agents | 1 | 2017 | 10 | 0.150 |
Why?
|
Retrospective Studies | 3 | 2018 | 2930 | 0.150 |
Why?
|
Decision Making | 1 | 2018 | 154 | 0.150 |
Why?
|
Positron-Emission Tomography | 3 | 2014 | 134 | 0.140 |
Why?
|
West Nile Fever | 1 | 2016 | 1 | 0.140 |
Why?
|
West Nile virus | 1 | 2016 | 1 | 0.140 |
Why?
|
Glucose Tolerance Test | 2 | 2015 | 134 | 0.140 |
Why?
|
Behavior Therapy | 1 | 2017 | 89 | 0.140 |
Why?
|
Geriatric Assessment | 1 | 2018 | 328 | 0.140 |
Why?
|
Polysomnography | 1 | 2016 | 31 | 0.140 |
Why?
|
Colorectal Neoplasms | 1 | 2018 | 206 | 0.140 |
Why?
|
Apolipoproteins E | 5 | 2014 | 101 | 0.140 |
Why?
|
Retinal Diseases | 1 | 2016 | 18 | 0.140 |
Why?
|
Prefrontal Cortex | 1 | 2016 | 33 | 0.140 |
Why?
|
Nervous System Diseases | 1 | 2016 | 36 | 0.140 |
Why?
|
Memory Disorders | 2 | 2008 | 57 | 0.140 |
Why?
|
Sleep Apnea, Obstructive | 1 | 2016 | 46 | 0.140 |
Why?
|
Purpura, Thrombocytopenic, Idiopathic | 1 | 2015 | 3 | 0.140 |
Why?
|
Dexamethasone | 1 | 2015 | 39 | 0.130 |
Why?
|
Insulin, Long-Acting | 1 | 2015 | 3 | 0.130 |
Why?
|
Pain | 2 | 2014 | 247 | 0.130 |
Why?
|
Research Design | 2 | 2014 | 271 | 0.130 |
Why?
|
Primary Health Care | 2 | 2014 | 174 | 0.130 |
Why?
|
Case-Control Studies | 2 | 2018 | 886 | 0.130 |
Why?
|
Ankle Brachial Index | 1 | 2014 | 37 | 0.130 |
Why?
|
Cerebellar Diseases | 1 | 2014 | 4 | 0.130 |
Why?
|
Cerebellar Cortex | 1 | 2014 | 4 | 0.130 |
Why?
|
Body Mass Index | 5 | 2019 | 890 | 0.130 |
Why?
|
Laminin | 1 | 2014 | 13 | 0.130 |
Why?
|
Naproxen | 2 | 2011 | 7 | 0.130 |
Why?
|
Dose-Response Relationship, Drug | 6 | 2015 | 436 | 0.130 |
Why?
|
Amyloid | 1 | 2014 | 17 | 0.130 |
Why?
|
Cysts | 1 | 2014 | 16 | 0.130 |
Why?
|
Sex Characteristics | 2 | 2013 | 158 | 0.130 |
Why?
|
CD8-Positive T-Lymphocytes | 1 | 2015 | 91 | 0.120 |
Why?
|
Pyrazoles | 2 | 2011 | 51 | 0.120 |
Why?
|
Fatigue | 1 | 2014 | 68 | 0.120 |
Why?
|
Exercise Test | 2 | 2016 | 192 | 0.120 |
Why?
|
Mental Status Schedule | 4 | 2017 | 24 | 0.120 |
Why?
|
Fluorodeoxyglucose F18 | 2 | 2011 | 51 | 0.120 |
Why?
|
Postoperative Complications | 1 | 2018 | 634 | 0.120 |
Why?
|
Arthralgia | 1 | 2013 | 30 | 0.120 |
Why?
|
gamma-Aminobutyric Acid | 1 | 2013 | 39 | 0.120 |
Why?
|
Risk Assessment | 1 | 2018 | 1285 | 0.110 |
Why?
|
Patient Selection | 1 | 2014 | 249 | 0.110 |
Why?
|
Administration, Intranasal | 4 | 2015 | 30 | 0.110 |
Why?
|
Psychotherapy, Group | 1 | 2012 | 15 | 0.110 |
Why?
|
Mental Recall | 3 | 2015 | 50 | 0.110 |
Why?
|
Population Surveillance | 1 | 2013 | 116 | 0.110 |
Why?
|
Prevalence | 4 | 2019 | 881 | 0.110 |
Why?
|
Neuropeptides | 1 | 2011 | 13 | 0.100 |
Why?
|
Radioimmunoassay | 1 | 2011 | 21 | 0.100 |
Why?
|
Insulin-Like Growth Factor Binding Protein 3 | 1 | 2011 | 21 | 0.100 |
Why?
|
Food, Formulated | 1 | 2011 | 10 | 0.100 |
Why?
|
Severity of Illness Index | 4 | 2012 | 846 | 0.100 |
Why?
|
Dietary Carbohydrates | 1 | 2011 | 21 | 0.100 |
Why?
|
Dietary Fats, Unsaturated | 1 | 2011 | 26 | 0.100 |
Why?
|
Risk Reduction Behavior | 1 | 2012 | 116 | 0.100 |
Why?
|
Oxidative Stress | 1 | 2013 | 249 | 0.100 |
Why?
|
Energy Metabolism | 2 | 2010 | 139 | 0.100 |
Why?
|
Body Composition | 1 | 2012 | 365 | 0.100 |
Why?
|
Cross-Over Studies | 1 | 2010 | 90 | 0.100 |
Why?
|
Thromboxane B2 | 1 | 2010 | 6 | 0.090 |
Why?
|
6-Ketoprostaglandin F1 alpha | 1 | 2010 | 3 | 0.090 |
Why?
|
Glucose Clamp Technique | 1 | 2010 | 13 | 0.090 |
Why?
|
Blood Pressure | 1 | 2014 | 861 | 0.090 |
Why?
|
Brain-Derived Neurotrophic Factor | 1 | 2010 | 29 | 0.090 |
Why?
|
Body Fat Distribution | 1 | 2010 | 36 | 0.090 |
Why?
|
Brain Chemistry | 2 | 2013 | 20 | 0.090 |
Why?
|
Anticholesteremic Agents | 1 | 2010 | 37 | 0.090 |
Why?
|
Residence Characteristics | 1 | 2011 | 166 | 0.090 |
Why?
|
Psychiatric Status Rating Scales | 3 | 2017 | 87 | 0.090 |
Why?
|
Patient Education as Topic | 3 | 2017 | 235 | 0.090 |
Why?
|
Hypercholesterolemia | 1 | 2010 | 61 | 0.090 |
Why?
|
tau Proteins | 3 | 2017 | 37 | 0.090 |
Why?
|
Octreotide | 1 | 2009 | 3 | 0.090 |
Why?
|
Gastrointestinal Agents | 1 | 2009 | 6 | 0.090 |
Why?
|
Oxygen Consumption | 1 | 2010 | 138 | 0.090 |
Why?
|
Somatostatin | 1 | 2009 | 9 | 0.090 |
Why?
|
Norepinephrine | 2 | 2006 | 54 | 0.090 |
Why?
|
Exercise Tolerance | 1 | 2010 | 110 | 0.080 |
Why?
|
Verbal Behavior | 1 | 2008 | 9 | 0.080 |
Why?
|
Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2010 | 133 | 0.080 |
Why?
|
Administration, Cutaneous | 2 | 2011 | 106 | 0.080 |
Why?
|
Cloprostenol | 1 | 2007 | 1 | 0.080 |
Why?
|
Thiazines | 1 | 2007 | 1 | 0.080 |
Why?
|
Exfoliation Syndrome | 1 | 2007 | 1 | 0.080 |
Why?
|
Carbonic Anhydrase Inhibitors | 1 | 2007 | 2 | 0.080 |
Why?
|
Ocular Hypertension | 1 | 2007 | 6 | 0.080 |
Why?
|
Quinoxalines | 1 | 2007 | 4 | 0.080 |
Why?
|
Glaucoma, Open-Angle | 1 | 2007 | 19 | 0.080 |
Why?
|
Adrenergic alpha-Agonists | 1 | 2007 | 38 | 0.080 |
Why?
|
Memory, Short-Term | 2 | 2019 | 41 | 0.080 |
Why?
|
Nutritional Physiological Phenomena | 1 | 2006 | 17 | 0.070 |
Why?
|
Organ Size | 2 | 2017 | 204 | 0.070 |
Why?
|
Hyperinsulinism | 1 | 2005 | 12 | 0.070 |
Why?
|
Prospective Studies | 2 | 2018 | 1932 | 0.070 |
Why?
|
Health Status | 2 | 2019 | 360 | 0.070 |
Why?
|
Thiazolidinediones | 1 | 2005 | 47 | 0.070 |
Why?
|
Regression Analysis | 2 | 2019 | 266 | 0.070 |
Why?
|
Activities of Daily Living | 2 | 2017 | 216 | 0.070 |
Why?
|
Area Under Curve | 2 | 2015 | 77 | 0.060 |
Why?
|
3-Hydroxybutyric Acid | 1 | 2004 | 3 | 0.060 |
Why?
|
Cytokines | 1 | 2005 | 239 | 0.060 |
Why?
|
Aptitude | 1 | 2004 | 2 | 0.060 |
Why?
|
Automobile Driving | 1 | 2004 | 19 | 0.060 |
Why?
|
Insulin-Like Growth Factor Binding Protein 1 | 1 | 2003 | 8 | 0.060 |
Why?
|
Alleles | 2 | 2014 | 273 | 0.060 |
Why?
|
Triglycerides | 1 | 2004 | 220 | 0.060 |
Why?
|
Adult | 5 | 2016 | 8243 | 0.060 |
Why?
|
Drug Administration Schedule | 1 | 2003 | 221 | 0.050 |
Why?
|
Cardiovascular Diseases | 1 | 2010 | 1059 | 0.050 |
Why?
|
Inflammation | 1 | 2005 | 501 | 0.050 |
Why?
|
Neuroprotective Agents | 1 | 2002 | 17 | 0.050 |
Why?
|
Cross-Sectional Studies | 2 | 2019 | 1345 | 0.050 |
Why?
|
Receptors, Estrogen | 1 | 2002 | 90 | 0.050 |
Why?
|
Pain Measurement | 2 | 2013 | 328 | 0.050 |
Why?
|
United States | 3 | 2016 | 3588 | 0.050 |
Why?
|
Magnetic Resonance Imaging | 2 | 2017 | 1144 | 0.050 |
Why?
|
Attention | 2 | 2014 | 61 | 0.040 |
Why?
|
Verbal Learning | 1 | 2019 | 8 | 0.040 |
Why?
|
Cerebrovascular Disorders | 1 | 2019 | 45 | 0.040 |
Why?
|
Indians, North American | 1 | 2019 | 111 | 0.040 |
Why?
|
Age Factors | 2 | 2016 | 1058 | 0.040 |
Why?
|
Animals | 4 | 2015 | 6402 | 0.040 |
Why?
|
Young Adult | 2 | 2016 | 2321 | 0.040 |
Why?
|
Prostatic Neoplasms | 1 | 2003 | 438 | 0.040 |
Why?
|
Synaptotagmins | 1 | 2018 | 1 | 0.040 |
Why?
|
Synaptophysin | 1 | 2018 | 2 | 0.040 |
Why?
|
F2-Isoprostanes | 2 | 2010 | 21 | 0.040 |
Why?
|
Odds Ratio | 1 | 2019 | 457 | 0.040 |
Why?
|
Drug Therapy, Combination | 2 | 2010 | 279 | 0.040 |
Why?
|
Preoperative Care | 1 | 2018 | 108 | 0.040 |
Why?
|
Contraceptive Agents, Female | 1 | 2017 | 15 | 0.040 |
Why?
|
Pilot Projects | 2 | 2011 | 437 | 0.040 |
Why?
|
Sensitivity and Specificity | 1 | 2019 | 521 | 0.040 |
Why?
|
Exosomes | 1 | 2018 | 37 | 0.040 |
Why?
|
Medroxyprogesterone Acetate | 1 | 2017 | 89 | 0.040 |
Why?
|
Disease Progression | 1 | 2019 | 566 | 0.040 |
Why?
|
Smoking | 1 | 2019 | 389 | 0.040 |
Why?
|
Interviews as Topic | 1 | 2017 | 240 | 0.040 |
Why?
|
Reproducibility of Results | 1 | 2018 | 700 | 0.040 |
Why?
|
Oximetry | 1 | 2016 | 28 | 0.040 |
Why?
|
Social Support | 1 | 2017 | 162 | 0.030 |
Why?
|
Immunotherapy, Adoptive | 1 | 2015 | 10 | 0.030 |
Why?
|
Lymphocyte Depletion | 1 | 2015 | 14 | 0.030 |
Why?
|
Incidence | 1 | 2019 | 1087 | 0.030 |
Why?
|
Platelet Glycoprotein GPIIb-IIIa Complex | 1 | 2015 | 32 | 0.030 |
Why?
|
T-Lymphocytes, Cytotoxic | 1 | 2015 | 35 | 0.030 |
Why?
|
Blood Platelets | 1 | 2015 | 37 | 0.030 |
Why?
|
Psychomotor Disorders | 1 | 2015 | 4 | 0.030 |
Why?
|
Space Perception | 1 | 2015 | 12 | 0.030 |
Why?
|
Feasibility Studies | 1 | 2016 | 247 | 0.030 |
Why?
|
Mice, Inbred BALB C | 1 | 2015 | 156 | 0.030 |
Why?
|
Radiography | 1 | 2016 | 339 | 0.030 |
Why?
|
Mice | 2 | 2015 | 2181 | 0.030 |
Why?
|
Muscular Dystrophies | 1 | 2014 | 3 | 0.030 |
Why?
|
Self Care | 1 | 2016 | 133 | 0.030 |
Why?
|
Aniline Compounds | 1 | 2014 | 24 | 0.030 |
Why?
|
Thiazoles | 1 | 2014 | 30 | 0.030 |
Why?
|
Prognosis | 1 | 2018 | 1342 | 0.030 |
Why?
|
Sequence Analysis, DNA | 1 | 2014 | 147 | 0.030 |
Why?
|
Mice, Knockout | 1 | 2015 | 392 | 0.030 |
Why?
|
Base Sequence | 1 | 2014 | 241 | 0.030 |
Why?
|
Hyperglycemia | 1 | 2014 | 82 | 0.030 |
Why?
|
Combined Modality Therapy | 1 | 2015 | 498 | 0.030 |
Why?
|
Weight Loss | 1 | 2017 | 411 | 0.030 |
Why?
|
Imaging, Three-Dimensional | 1 | 2014 | 128 | 0.030 |
Why?
|
Injections, Subcutaneous | 1 | 2013 | 25 | 0.030 |
Why?
|
Frontal Lobe | 1 | 2013 | 35 | 0.030 |
Why?
|
Cholesterol | 1 | 2015 | 231 | 0.030 |
Why?
|
Magnetic Resonance Spectroscopy | 1 | 2013 | 80 | 0.030 |
Why?
|
Cluster Analysis | 1 | 2013 | 122 | 0.030 |
Why?
|
Intention to Treat Analysis | 1 | 2012 | 22 | 0.030 |
Why?
|
Predictive Value of Tests | 1 | 2014 | 774 | 0.030 |
Why?
|
Clinical Protocols | 1 | 2012 | 86 | 0.030 |
Why?
|
Blood Glucose | 2 | 2006 | 485 | 0.030 |
Why?
|
Least-Squares Analysis | 1 | 2011 | 29 | 0.030 |
Why?
|
Immunoassay | 1 | 2011 | 11 | 0.030 |
Why?
|
Spinal Puncture | 1 | 2011 | 19 | 0.030 |
Why?
|
Disease Models, Animal | 1 | 2015 | 915 | 0.030 |
Why?
|
Hospitals, Veterans | 1 | 2011 | 33 | 0.030 |
Why?
|
Confidence Intervals | 1 | 2011 | 136 | 0.030 |
Why?
|
Body Weight | 1 | 2013 | 289 | 0.020 |
Why?
|
Child, Preschool | 1 | 2014 | 1126 | 0.020 |
Why?
|
Aspirin | 1 | 2010 | 59 | 0.020 |
Why?
|
Proportional Hazards Models | 1 | 2011 | 706 | 0.020 |
Why?
|
Homeostasis | 1 | 2010 | 140 | 0.020 |
Why?
|
Acetylcholine | 1 | 2009 | 38 | 0.020 |
Why?
|
Adolescent | 1 | 2016 | 3184 | 0.020 |
Why?
|
Child | 1 | 2014 | 2151 | 0.020 |
Why?
|
Intraocular Pressure | 1 | 2007 | 27 | 0.020 |
Why?
|
Circadian Rhythm | 1 | 2007 | 39 | 0.020 |
Why?
|
Diabetes Mellitus | 1 | 2010 | 366 | 0.020 |
Why?
|
Japan | 1 | 2006 | 17 | 0.020 |
Why?
|
Injections, Intravenous | 1 | 2006 | 56 | 0.020 |
Why?
|
Prealbumin | 1 | 2005 | 8 | 0.020 |
Why?
|
Interleukin-1 | 1 | 2005 | 35 | 0.020 |
Why?
|
PPAR gamma | 1 | 2005 | 45 | 0.020 |
Why?
|
Asian Continental Ancestry Group | 1 | 2006 | 114 | 0.020 |
Why?
|
Interleukin-6 | 1 | 2005 | 224 | 0.020 |
Why?
|
Tumor Necrosis Factor-alpha | 1 | 2005 | 203 | 0.020 |
Why?
|
Ketone Bodies | 1 | 2004 | 6 | 0.020 |
Why?
|
Mental Competency | 1 | 2004 | 4 | 0.020 |
Why?
|
Language | 1 | 2004 | 43 | 0.020 |
Why?
|
Amyloid beta-Protein Precursor | 1 | 2003 | 6 | 0.010 |
Why?
|
Psychomotor Performance | 1 | 2004 | 59 | 0.010 |
Why?
|
Homozygote | 1 | 2003 | 61 | 0.010 |
Why?
|
Neoplasm Transplantation | 1 | 2003 | 75 | 0.010 |
Why?
|
Cell Division | 1 | 2003 | 97 | 0.010 |
Why?
|
Transplantation, Heterologous | 1 | 2003 | 120 | 0.010 |
Why?
|
Prostate | 1 | 2003 | 68 | 0.010 |
Why?
|
Epithelial Cells | 1 | 2003 | 139 | 0.010 |
Why?
|
Cell Line | 1 | 2003 | 418 | 0.010 |
Why?
|
Immunohistochemistry | 1 | 2003 | 515 | 0.010 |
Why?
|
Cerebrovascular Circulation | 1 | 2002 | 90 | 0.010 |
Why?
|
Clinical Trials as Topic | 1 | 2002 | 293 | 0.010 |
Why?
|